PRevalence Of Transient Global Amnesia in Obstructive Sleep Apnea Syndrome
Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Mar 24, 2025
Trial Information
Current as of April 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called Transient Global Amnesia (TGA), which is a temporary loss of memory that can last less than 24 hours. The researchers want to explore the connection between TGA and obstructive sleep apnea, a condition where breathing repeatedly stops and starts during sleep. They aim to gather more information by including 200 to 250 participants, as a smaller study suggested there might be a link. Understanding this relationship better could lead to new treatment options in the future.
To be eligible for this study, participants must be adults aged 65 to 74 who have experienced an episode of amnestic stroke, which is a specific type of memory loss episode documented by a witness. They should not have other serious memory problems or a history of recent head injuries or epilepsy. If you decide to participate, you will help researchers gain valuable insights that could improve care for people with these conditions. It’s important to know that your data will be used for research purposes, but only if you agree to it.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Adult patients seen for consultation in the Neuropsychology Department of Strasbourg University Hospital between March 1, 2015 and December 31, 2021 following an episode of amnestic stroke meeting the Hodges and Warlow criteria:
- • The stroke must have been documented and reported by a competent witness present during the stroke.
- • Anterograde amnesia during the stroke.
- • Absence of vigilance, personality, and cognitive disorders other than memory disorders (aphasia, apraxia, etc.).
- • Absence of focal neurological symptoms during the episode and its aftermath.
- • Absence of epileptic manifestations.
- • Resolution of the episode in less than 24 hours.
- • Exclusion of patients with a history of recent head trauma or active epilepsy (undergoing regular treatment or having experienced a seizure in the last 2 years).
- • Subjects who have not expressed opposition to the reuse of their data for scientific research purposes.
- Exclusion Criteria:
- • Patients who have expressed opposition to the retrospective reuse of their data for scientific research purposes.
- • Patients with active epilepsy
- • Patients with recent head trauma
- • Patients with an MMS \< or equal to 25
- • Subject under guardianship or curatorship
- • Subject under judicial protection
About University Hospital, Strasbourg, France
The University Hospital of Strasbourg, France, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the institution collaborates with a diverse range of healthcare professionals and research teams to explore cutting-edge therapies and treatment modalities. With state-of-the-art facilities and a multidisciplinary approach, the University Hospital of Strasbourg plays a pivotal role in translating scientific discoveries into effective clinical applications, contributing significantly to the advancement of medical knowledge and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Strasbourg, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported